Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial

Abstract

BackgroundIn recent years, red yeast rice (RYR) supplements have been marketed aggressively as a natural way to lower cholesterol; however, the large majority of commercially available products have not been studied according to current research standards.MethodsIn a double blind placebo controlled randomized trial, 52 physicians and their spouses with a total cholesterol level of > 200 mg/dL were randomly allocated to receive a RYR extract or placebo for 8 weeks. As a primary outcome measure, we compared the before-after difference in lipid levels between both groups. As secondary outcome measures we looked at side-effects, CK elevation and a change in cardiovascular risk.ResultsLDL (low density lipoprotein) cholesterol was lowered with 36 mg/dL (22%) and total cholesterol with 37 mg/dL (15%) in the intervention group. This result was statistically significant as compared to the control group, in which no reduction in total cholesterol and LDL was observed (p < 0.001). There was no marked difference in CK (creatine kinase)-elevation or reported side-effects between study groups. In 5/31 participants in the intervention group, the lipid lowering effect resulted in lower cardiovascular risk as measured with SCORE (Systematic COronary Risk Evaluation).ConclusionsThe RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in this study population. RYR therapy may be an attractive and relatively well studied alternative in patients who are intolerant for statins or who have objections against pharmacological lipid lowering. However, consumers need to be warned that the actual content of commercially available preparations is not assured by governmental regulations, which raises effectiveness and safety issues.Trial registrationClinicaltrials.gov, nr: NCT01558050

The use of probiotic L. fermentum ME-3 containing Reg’Activ Cholesterol supplement for 4 weeks has a positive influence on blood lipoprotein profiles and inflammatory cytokines: an open-label preliminary study

“…The RAC contains monacolin K that is an inhibitor of cholesterol synthesis key-enzyme [38, 39]. The RAC formula also contains vitamin E and ubiquinol (vitamin Q), both working in the human body as powerful antioxidants.…”

Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements

“…37 LDL was reduced by 22.17% in the subjects in the red yeast rice arm (P < 0.001) of the study, with a formulation equivalent to 10 mg of daily monacolin K.…”

Therapeutic properties of rice constituents and derivatives (Oryza sativa L.): A review update

“…In another experimental study on a rat model of hyperlipidemia, red yeast rice has been found to regulate the balance between blood coagulation and anticoagulation factors, thereby preventing the formation of thrombus and reducing the occurrence of atherosclerosis (Lee, Shih et al 2013) A study aimed at disclosing the mechanism of action of red yeast rice, based on a nonalcoholic fatty liver disease mouse model, has suggested that the therapeutic effect of the product would be independent of monacolin K levels, whereas it should be rather ascribed to GABA and various peptides produced during rice fermentation (Fujimoto, Tsuneyama et al 2012). Conversely, doubleblind clinical studies on hypercholesterolemic subjects have shown that dietary monacolin K is able to reduce cholesterolemia (Cicero, Derosa et al 2013;Verhoeven, Lopez Hartmann et al 2013). …”